22–74K Americans die from influenza each year.
In high-risk populations, current vaccines fail.
Season-long non-vaccine protection could prevent hundreds of thousands of hospitalizations in immunocompromised, comorbid, and ≥65y populations where immune-dependent vaccines deliver 5–35% effectiveness. This platform quantifies the burden, maps the evidence, and models the preventable events.
360–740K annual US influenza hospitalizations under current vaccine SOC — with 22–74K deaths per year and $11.2B in direct + indirect costs. Explore consequence funnel
From Population at Risk to Preventable Value
Six chapters that build the Investigational Prophylactic value story. Click any tile to jump.
What's in the library
Publication Trend
US publications by year (SLR corpus)
Solid uptick post-2020 with 2024 as densest year; 2026 partial through June.
Outcome Coverage
Distribution of endpoint categories (US)
Vaccine effectiveness dominates; healthcare resource utilization second.
18 Modules · One Story
Every burden view carries the Investigational Prophylactic counterfactual overlay. Chat with the RWE agent from any page.